EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211

Kazuko Kaneda-Nakashima iD, Yoshifumi Shirakami iD, Kentaro Hisada, Sifan Feng, Yuichiro Kadonaga, Kazuhiro Ooe iD, Tadashi Watabe iD, Yoshiyuki Manabe iD, Atsushi Shimoyama iD, Masashi Murakami iD, Atsushi Toyoshima, Hiromitsu Haba und 2 weitere

International Journal of Molecular Sciences · 18.11.2024 · 25 (22) · 12386

DOI: 10.3390/ijms252212386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.11.2024. Verfasst von Kazuko Kaneda-Nakashima und 13 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Biological Chemistry, MS-CORE, FRC, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan. Hauptthemen laut MEDLINE: Astatine, Large Neutral Amino Acid-Transporter 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sumitomo Foundation, Japan Agency for Medical Research and Development, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated nuclear medicine therapeutics targeting the L-type amino acid transporter 1 (LAT1). We previously reported that a nuclear medicine therapeutic drug using astatine 211 (211At), an alpha-emitting nuclide that can be produced in an accelerator and targets LAT1 as a molecular target, is effective. The seed compound was 3-[211At] Astato-α-methyl-L-tyrosine (211At-AAMT-OH-L). We used a unique labeling method. By changing the OH group of phenol to a methyl group, retention was successfully increased. It was also found that the amount of the L-isomer taken up by the D-isomer and L-isomer was clearly higher, and the L-isomer was superior as a therapeutic drug. Compounds in which the methyl group was replaced with an ethyl or propyl group were also examined, but their retention did not increase significantly. In fact, we observed increased non-specific accumulation and dynamics, suggesting that labeling may be off. In addition, 211At-AAMT-O-Me-L, which has a simple structure, was clearly superior in terms of uptake speed for several candidate compounds. As a result, we were able to develop a compound that can be easily labeled, has high specific radioactivity, is stable, and has a strong therapeutic effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstatineLarge Neutral Amino Acid-Transporter 1HumansNuclear MedicineRadiopharmaceuticalsAnimalsCell Line, Tumor

Stichwörter der Autor:innen

LAT1amino acidastatine-211cancer therapynuclear medicine

Substanzen

AstatineLarge Neutral Amino Acid-Transporter 1Astatine-211Radiopharmaceuticals

Autor:innen und Institutionen

  • Radiation Biological Chemistry, MS-CORE, FRC, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.
  • Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Department of Radiology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.
  • Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
  • Premium Research Institute for Human Metaverse Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

ORCID-Profile: Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Kazuhiro Ooe, Tadashi Watabe, Yoshiyuki Manabe, Atsushi Shimoyama, Masashi Murakami, Koichi Fukase

Förderung

  • Sumitomo Foundation
  • Japan Agency for Medical Research and Development
  • JSPS KAKENHI
  • Foundation for the Promotion of Cancer Research
  • AMED

Zitieren

APA

Kaneda-Nakashima, K., Shirakami, Y., Hisada, K., Feng, S., Kadonaga, Y., Ooe, K., Watabe, T., Manabe, Y., Shimoyama, A., Murakami, M., Toyoshima, A., Haba, H., Kanai, Y., & Fukase, K. (2024). Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211. International Journal of Molecular Sciences, 25(22), 12386. https://doi.org/10.3390/ijms252212386

Vancouver

Kaneda-Nakashima K, Shirakami Y, Hisada K, Feng S, Kadonaga Y, Ooe K, et al. Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211. International Journal of Molecular Sciences. 2024;25(22):12386. doi:10.3390/ijms252212386

BibTeX
@article{KanedaNakashima2024,
  author = {Kaneda-Nakashima, Kazuko and Shirakami, Yoshifumi and Hisada, Kentaro and Feng, Sifan and Kadonaga, Yuichiro and Ooe, Kazuhiro and Watabe, Tadashi and Manabe, Yoshiyuki and Shimoyama, Atsushi and Murakami, Masashi and Toyoshima, Atsushi and Haba, Hiromitsu and Kanai, Yoshikatsu and Fukase, Koichi},
  title = {Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {22},
  pages = {12386},
  doi = {10.3390/ijms252212386}
}
Kostenlos starten →